申请人:Merck & Co., Inc.
公开号:US06350760B1
公开(公告)日:2002-02-26
Certain novel substituted piperidine compounds are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction. Also provided are methods of treating sexual dysfunction with a compound that is a selective agonist of MC-4R over any other human melanocortin receptor.
某些新型替代哌啶化合物是人类黑色素皮质素受体的激动剂,特别是人类黑色素皮质素-4受体(MC-4R)的选择性激动剂。因此,它们对于治疗、控制或预防对MC-4R激活敏感的疾病和紊乱是有用的,例如肥胖症、糖尿病、性功能障碍,包括勃起功能障碍和女性性功能障碍。还提供了使用对MC-4R具有选择性激动剂的化合物治疗性功能障碍的方法,而不是其他任何人类黑色素皮质素受体。